RECKGIST score effectively predicts recurrence in neurofibromatosis type 1-associated GISTs, especially for tumors under 30 mm. Larger GISTs (over 30 mm) have a higher risk of metastasis, with ...

Women with early-stage hormone receptor (HR)-positive breast cancer who had low to intermediate scores on the Oncotype DX Breast Recurrence Score assay did just as well on neoadjuvant endocrine ...

A retrospective study validates the Oncotype 21-gene breast recurrence score as a predictive biomarker of adjuvant chemotherapy benefit in women with estrogen receptor (ER)-positive/human epidermal ...

Please provide your email address to receive an email when new articles are posted on . Further study is needed to identify potential drivers of the association Low household income appeared ...

Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor–Positive Breast Cancer ...

The Oncotype DX Breast Recurrence Score® test, which has been used by over 1.5 million patients, indicates the likelihood of your cancer recurring based on the biology of your tumor. 1,2,3,4 It is ...

"We have known that income level is associated with incidence of poor-prognosis triple-negative breast cancer, but our new study presents the first data to show that income level impacts survival even ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Outcomes among women with breast cancer who have similar 21-gene recurrence scores may vary by ...

Peer-reviewed manuscript demonstrates the Endocrine Activity IndexTM Recurrence Risk (EAIRR) enhances risk stratification ...

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast ...